Jiangsu Yahong Meditech Co Ltd

Jiangsu Yahong Meditech’s APL‑1702 gets China’s first NMPA approval for cervical pre‑cancer therapy, sparking a 20% share rally and a push toward global expansion.

Jiangsu Yahong Meditech Co Ltd has announced positive preliminary results from a clinical trial for APL-1401, boosting investor confidence and market activity.

Jiangsu Yahong Meditech Co Ltd has demonstrated resilience and strategic growth in China’s medical technology sector, positioning itself for continued success and leadership in the industry.

Jiangsu Yahong Meditech Co Ltd’s stock price has experienced a dramatic rollercoaster ride on the Shanghai Stock Exchange, with significant fluctuations over the past year leaving investors questioning the company’s stability and future prospects.